Capreomycin (sulfate)

Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease[1][2][3][4][5].

Product Specifications

CAS Number

[1405-37-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial

Type

Natural Products

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Capreomycin-sulfate.html

Purity

99.52

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

OS(O)(=O)=O.[R]C[C@H](N1)C(N[C@@H](CNC(CC(N)CCCN)=O)C(N/C(C(N[C@H](C(NC[C@H](N)C1=O)=O)[C@@H]2NC(NCC2)=N)=O)=C\NC(N)=O)=O)=O.OS(O)(=O)=O.[R=OH1A].[R=H1B]

Molecular Weight

638.61

Precautions

H302, H315, H319, H335

References & Citations

[1]Maus CE, et al. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005 Feb;49 (2) :571-7.|[2]Garcia-Contreras L, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007 Aug;51 (8) :2830-6.|[3]Siddiqi M K, et al. Capreomycin inhibits the initiation of amyloid fibrillation and suppresses amyloid induced cell toxicity[J]. Biochimica et Biophysica Acta (BBA) -Proteins and Proteomics, 2018, 1866 (4) : 549-557.|[4]Reisfeld B, et al. A physiologically based pharmacokinetic model for capreomycin[J]. Antimicrobial agents and chemotherapy, 2012, 56 (2) : 926-934.|[5]Le Conte P, et al. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model[J]. Antimicrobial agents and chemotherapy, 1994, 38 (12) : 2695-2701.